Functional Outcome of Cemented Primary Total Hip Arthroplasty

Abstract

Objective

To determine the efficacy of cemented primary total hip replacement in patients with end-stage hip disease.

Methods

The study was conducted at Khyber Teaching Hospital Peshawar, Pakistan, from March 2022 to January 2024. The study involved 50 males and 23 females and aged 40-80 years, who underwent cemented total hip arthroplasty for end-stage hip diseases. The participants underwent a thorough history, physical examination, and Harris hip score to evaluate their functional ability. All arthroplasties were performed through a modified Hardinge lateral approach using a cemented total hip prosthesis under spinal anesthesia. The patients were mobilized with crutches on the first postoperative day and received intravenous antibiotics for 3 days. The Harris hip score was monitored at 3 months postoperatively and analyzed using SPSS-23 and paired T-test keeping a p-value of ≤ 0.05 as significant.

Results

Most hip involvement was right, with 62% being right hip involvement. Hip pain was the main complaint. The Harris Hip Score was 10-32, with a mean value of 16.50±4.83 preoperatively while postoperatively, in the 3rd month, it was 86.34±9.84 with a p-value of <0.00001 which is significant. The Harris hip score was good to excellent at 82%, fair at 12%, and poor in 5% of cases in 3rd month postoperatively. Complications included skin surgical site infections and dislocations.

Conclusion:

Cemented total hip arthroplasty is a safe and successful treatment for end-stage hip joint diseases, providing patients with the possibility of regaining mobility, reducing discomfort, and improving quality of life with minimum risk of complications.